News, discussion, expert analysis and data on ASX shares - ShareCafe

Time 2020-11-05 04:03:35

Web Name: News, discussion, expert analysis and data on ASX shares - ShareCafe

WebSite: http://www.sharecafe.com.au

ID:105373

Keywords:

analysis,and,expert,

Description:

DNR Capital Discuss The Outlook For Dividend Growth FUNDS Bell Potter June ETF Report: Defending Against Cyber AttacksBell Potter analyst William Gormly provides a summary of the ETF market in June and highlights BetaShares Global Cybersecurity ETF which provides exposure to a diversified portfolio of cybersecurity companies in the world. MORE FUNDS LICs Bell Potter LIC Weekly: CLF Hits A PremiumBell Potter analyst William Gormly updates developments in the LIC market where after trading at a persistent discount to its pre-tax NTA, Concentrated Leaders Fund has achieved a new milestone. MORE LICs MARKETS Understanding Pre-IPO Investing How To Generate Returns And Avoid The PitfallsPre-IPO investing has the potential to generate significant returns in a relatively short space of time, however there are many issues to consider that may not be obvious to the regular investor. MORE MARKETS COMMODITIES Virus Unlikely To Impede Demand For MetalsSilver and copper appear on an upward trajectory and remain highly leveraged to a Biden or Trump infrastructure push. Clearly, copper with all its green energy applications will be more in demand under Biden’s plan. MORE COMMODITIESDOWNLOAD RESEARCH REPORTAnd a Door Opens WideAntisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.DOWNLOAD RESEARCH REPORTFit for tough times; prepared for coal’s upswingTerracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.DOWNLOAD RESEARCH REPORTA Laser-Like Focus on Adding ValueSince August 1st, Kazia Therapeutics has announced US Food Drug Administration fast track status for one program orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

TAGS:analysis and expert 

<<< Thank you for your visit >>>

News, expert commentary, discussion, analysis and data on the ASX, Australian share market, economy, finance and international shares.

Hot Websites